(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 1.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Apellis Pharmaceuticals's revenue in 2025 is $1,016,397,000.On average, 22 Wall Street analysts forecast APLS's revenue for 2025 to be $127,537,419,744, with the lowest APLS revenue forecast at $86,581,206,677, and the highest APLS revenue forecast at $139,557,315,454. On average, 22 Wall Street analysts forecast APLS's revenue for 2026 to be $111,901,433,304, with the lowest APLS revenue forecast at $97,661,020,018, and the highest APLS revenue forecast at $126,904,793,654.
In 2027, APLS is forecast to generate $135,002,407,606 in revenue, with the lowest revenue forecast at $114,038,444,236 and the highest revenue forecast at $175,743,527,802.